Federal Scrutiny on Unregulated Cannabinoid Products
The US House Appropriations Committee has issued a draft report calling for increased enforcement against the proliferation of unregulated cannabinoid products. The report specifically targets “Federally unregulated ingestible, inhalable, and topical products that contain intoxicating cannabinoids,” asserting that these items “threaten consumer safety.” This directive urges the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) to address the issue, as reported by Marijuana Moment.
In a related federal development, the House Rules Committee is considering an amendment that would allow Department of Veterans Affairs (VA) doctors to recommend medical cannabis to military veterans. This amendment is slated for a floor vote, potentially expanding access pathways for veterans seeking medical cannabis. Separately, an amendment aimed at raising awareness for psychedelic and other therapeutic options for military veterans is also advancing through the legislative process.
Outgoing FDA Commissioner Marty Makary noted in his resignation message to President Donald Trump that he “wrote new guidance to advance psychedelics” as part of his accomplishments, indicating ongoing federal interest in the regulatory framework for these substances.
State-Level Policy Developments and Access Expansion
Across various US states, legislative and regulatory bodies are implementing changes to medical cannabis access and related policies:
- Georgia: Governor Brian Kemp signed a bill expanding medical cannabis access. The legislation introduces new qualifying conditions, permits vaping as a consumption method, and modifies existing THC potency limits for medical products.
- Iowa: Lawmakers have advanced a bill to Governor Kim Reynolds that would double the number of licensed medical cannabis dispensaries in the state. The proposed legislation also includes provisions to allow out-of-state residents to register in Iowa’s medical cannabis program, provided they hold a certification from an Iowa healthcare provider.
- Indiana: The Indiana Board of Pharmacy held preliminary discussions regarding the potential impact of federal marijuana rescheduling. Board members noted their authority to object to automatically mirroring any federal changes at the state level, indicating a cautious approach to regulatory alignment.
- Nebraska: Regulators have voted to permit medical cannabis cultivation businesses to commence growing operations immediately upon passing inspection, streamlining the initial phase of licensed production.
- Oklahoma: Lawmakers sent a bill to Governor Kevin Stitt supporting clinical trials for ibogaine. The initiative aims to investigate the psychedelic compound for conditions such as substance use disorders and traumatic brain injuries.
Legal Precedents and Market Activity
Legal and business developments continue to shape the broader cannabis and related industries:
- United Kingdom: The UK Employment Appeal Tribunal ruled that the dismissal of a rail worker due to medical cannabis use might constitute disability discrimination. This decision could establish a precedent for employment law concerning medical cannabis patients.
- Arizona: The Arizona Corporation Commission has ordered a marijuana payment processor company and an operator to pay restitution and administrative penalties. The penalties stem from alleged violations of securities registration regulations.
- Market Performance: Several publicly traded cannabis companies reported their quarterly financial results. Vireo Growth Inc. reported quarterly revenue of $106.2 million. Jushi Holdings Inc. posted quarterly net revenue of $66.4 million and a net loss of $19.8 million. Village Farms International, Inc. reported quarterly revenue of $50.2 million. Organigram Global Inc. recorded quarterly net revenue of C$59.8 million and a net loss of C$0.9 million. WM Technology, Inc. reported quarterly revenue of $43.6 million.
- Mergers & Acquisitions: Emerald Holding, Inc., the parent company of MJBizDaily, is being acquired by funds managed by Apollo.
- Research: A review of studies concluded that adjunctive CBD showed a “statistically significant, albeit small, advantage” over placebo for total, positive, and general symptoms in schizophrenia.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
